SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Update adrenal tumour guidelines, experts say
Tues June 25th - Global guidelines on the care of patients with adrenal tumours need up-dating, experts reported last night. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Hope for new lung cancer therapy

Thursday December 27th, 2018

UK researchers are investigating the use of drugs commonly used for breast cancer to treat drug-resistant lung cancer.

Results of studies involving laboratory mice were reported last night.

Professor Julian Downward from the Francis Crick Institute and the Institute of Cancer Research, London, UK, and colleagues examined drugs that block a protein called p110a. This protein is part of a family of proteins involved in cellular functions such as cell growth, proliferation, differentiation and movement.

The researchers were particularly interested in the interactions between p110a and the EGFR gene, which is mutated in some cancers, causing uncontrolled cell growth.

They tested genetically modified mice and found that lung tumours caused by mutations in EGFR "shrank significantly" when p110a was blocked, with very few side effects.

Details appeared yesterday (26 December) in Cell Reports. The authors report that p110a inhibitors are already being tested in breast cancer trials, so could be approved soon.

Professor Downward says: "At the moment, patients with EGFR-mutant lung cancers are given targeted treatments that are very effective for the first few years.

These drugs are improving, but unfortunately after a couple of years the cancer usually becomes resistant and starts to grow and spread again. The second line of treatment is currently conventional chemotherapy, which is not targeted and has substantial side-effects.

"Our new study suggests that it would be worth investigating whether p110a inhibitors could be used as a second-line therapy. As our research is at such an early stage, more research in mice and patient cells would be needed before even considering clinical trials, but it opens up a promising avenue of investigation."

Downward, J. et al. Cell Reports 26 December 2018

Tags: Cancer | Genetics | Pharmaceuticals | Respiratory | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES